Jingming joined the Office of Entrepreneurship and Commercialization in January 2024 as an Immunotherapy Project Manager. In 2025, she joined OEC’s Digital Health team, where she leads efforts to expand MSK’s AI-driven drug development technologies through strategic partnerships with biotech companies.
Previously, Jingming worked on small molecule AI-driven drug discovery at Roivant Sciences – VantAI, and served as a Client Relationship Manager at Genesis Biotechnology Group.
Jingming conducted her fellowship in cancer immunotherapy at MSKCC from 2019 to 2021.